JUN 03, 2016 8:46 AM PDT

FDA Clears New Diagnostic Agent for Detection of Rare Tumors

WRITTEN BY: Xuan Pham
After earning priority review status, the French-based pharmaceutical company Advanced Accelerator Applications just received FDA approval for a new agent to image neuroendocrine tumors (NET). Marketed under the name Netspot, the kit prepares a radioactive agent that helps doctors spot and treat the rare tumors. Outside of the U.S. Netspot is known as Somakit-TATE.

"Use of advanced imaging techniques to detect rare neuroendocrine tumors at an early stage in patients is critical," said Libero Marzella, director of the Division of Medical Imaging Products in the FDA's Center for Drug Evaluation and Research. "Netspot provides another diagnostic tool whose results will help clinicians determine the location and extent of the tumor. This information is important for planning the appropriate course of therapy."

Neuroendocrine tumors (NETs) form from abnormal neuroendocrine cells, which are hormone cells found throughout the body, especially in the lungs, stomach and intestines. This tumor type is rare, but still affects over 47,000 people in the US and European Union annually. Sometimes benign but sometimes cancerous, the tumor can lurk undetected for years and delay diagnosis and treatment. Thus with surgery, chemotherapy, and/or radiotherapy interventions, the five-year survival rate still hovers between 50 to 60 percent.
 

Netspot is a diagnostic solution to detecting NETs. The single-dose kit prepares a radioactive substance, known as gallium Ga 68 dotatate, as an injectable. This radioconjugate has the capacity to bind to somatostatin receptors that are present on the hormone-producing NETs. Then, positron emission tomography (PET) imaging reveals the locations of these tumors. Uptake of the Ga 68 dotatate also reveals the density of the tumors. From a chemical affinity perspective, Ga 68 dotatate binds to the somatostatin receptors much stronger than the body’s somatostatin hormone. This allows for clear and accurate visualization of the tumors, if they are present.

The new intervention has already undergone three clinical trials, in which its safety and efficacy was stringently tested. In one of the trials, the company compared Netspot against standard imaging techniques and demonstrated that Netspot performed better. They reported no adverse reactions from Netspot.

Following the approval, the company plans to make Netspot available to doctors as soon as possible. They note that although NETs are designated as rare tumors, otherwise called an “orphan disease,” the incidence of this tumor has grown over 500 percent over the past 30 years. As such, making better diagnostic tools available for the detection of these tumors can yield better outcome for the patients involved.

Additional source: Advanced Accelerator Applications press release
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 07, 2021
Cancer
Does inhibiting NLRP3 inhibit melanoma tumor growth?
APR 07, 2021
Does inhibiting NLRP3 inhibit melanoma tumor growth?
Researchers at the University of Colorado Cancer Center have published exciting findings in the Proceedings of the Natio ...
APR 25, 2021
Genetics & Genomics
How Did the Chernobyl Disaster Affect Human Health?
APR 25, 2021
How Did the Chernobyl Disaster Affect Human Health?
It's been about 35 years since the disaster at the Chernobyl nuclear power plant. Now researchers have investigated whet ...
MAY 05, 2021
Cancer
Developing Therapies to Combat Drug-Resistant Cell States
MAY 05, 2021
Developing Therapies to Combat Drug-Resistant Cell States
Drug resistant tumors present challenges in cancer treatment A significant challenge in the treatment of cancers is the ...
MAY 07, 2021
Cancer
Pandemic times haven't been fun for anyone, but they've been especially hard for cancer patients
MAY 07, 2021
Pandemic times haven't been fun for anyone, but they've been especially hard for cancer patients
The pandemic hit everyone hard on many levels; now, new research from UCSF published in Cancer reports that cancer patie ...
MAY 09, 2021
Cancer
Vegetarian diet shows low levels of disease-related biomarkers
MAY 09, 2021
Vegetarian diet shows low levels of disease-related biomarkers
Researchers from the University of Glasgow have conducted a study on biomarkers in order to glean more information on th ...
JUN 15, 2021
Cancer
Red seaweed consumption is associated with a low risk of colon cancer - but why?
JUN 15, 2021
Red seaweed consumption is associated with a low risk of colon cancer - but why?
New research published in Marine Drugs explains why diets high in red seaweed are associated with a low risk of col ...
Loading Comments...